SCHEMBL12009103

SCHEMBL12009103

CCOC(=O)c1cccc(-n2c(C)cc(C=C3SC(=O)N(c4ccccc4)C3=O)c2C)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 6/20 0.63
▸ ALDH1A1 P00352 10/20 0.62
▸ LMNA P02545 2/20 0.62
▸ SMN1; SMN2 Q16637 1/20 0.62
▸ TCF4 P15884 1/20 0.60
▸ CTNNB1 P35222 1/20 0.60
▸ HDAC6 Q9UBN7 1/20 0.60
▸ MEN1 O00255 8/20 0.54
▸ KMT2A Q03164 8/20 0.54
▸ MAPT P10636 7/20 0.54
▸ KDM4E B2RXH2 4/20 0.54
▸ MAPK1 P28482 3/20 0.51
▸ RAB9A P51151 4/20 0.51
▸ NPC1 O15118 4/20 0.51
▸ NPSR1 Q6W5P4 2/20 0.51
▸ HTT P42858 1/20 0.49
▸ CTDSP1 Q9GZU7 2/20 0.49
▸ NSD2 O96028 1/20 0.49
▸ APEX1 P27695 1/20 0.49
▸ RECQL P46063 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12009071 0.92 TCF4 (0.61) POLBALDH1A1LMNASMN1; SMN2TCF4
SCHEMBL12009039 0.91 POLB (0.65) POLBALDH1A1LMNASMN1; SMN2TCF4
SCHEMBL12009077 0.88 POLB (0.79) POLBALDH1A1TCF4CTNNB1HDAC6
SCHEMBL18545611 0.88 POLB (0.79) POLBALDH1A1TCF4CTNNB1HDAC6
SCHEMBL13446962 0.88 POLB (0.68) POLBALDH1A1SMN1; SMN2TCF4CTNNB1
SCHEMBL13464569 0.85 POLB (0.60) POLBALDH1A1LMNASMN1; SMN2TCF4
SCHEMBL12009045 0.85 TCF4 (0.55) POLBALDH1A1LMNASMN1; SMN2TCF4
SCHEMBL18545441 0.84 POLB (0.58) POLBALDH1A1LMNASMN1; SMN2TCF4
SCHEMBL12009027 0.84 POLB (0.58) POLBALDH1A1LMNASMN1; SMN2TCF4
SCHEMBL12009120 0.83 TCF4 (0.73) POLBALDH1A1SMN1; SMN2TCF4CTNNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9433611-B2 Oxazole and thiazole compounds as β-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2016-09-06 — — US disclosed
US-9173871-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2015-11-03 — — US disclosed
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF NEW YORK UNIVERSITY 2013-05-02 — — US disclosed
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF UNITED STATES GOVERNMENT 2012-10-18 — — US disclosed
US-8252823-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2012-08-28 — — US disclosed
US-8252823-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2012-08-28 — — US disclosed
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof US ARMY, SECRETARY OF THE ARMY 2009-09-10 — — US disclosed
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof US ARMY, SECRETARY OF THE ARMY 2009-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 POLB 2397/4885ALDH1A1 935/4885LMNA 3384/4885
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof CTNNB1, CTNNA1, CTNNBL1 POLB 2088/4885ALDH1A1 413/4885LMNA 4032/4885
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 POLB 2088/4885ALDH1A1 413/4885LMNA 4032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback